A developer of feeds for farmed salmon says its algae-based feed supplements could arrest the sharp decline in omega-3 fatty acids discovered in a recent study. . . . → Read More: Algae Feed Proposed to Enrich Farm Salmon Fatty Acids
|
|||||
A developer of feeds for farmed salmon says its algae-based feed supplements could arrest the sharp decline in omega-3 fatty acids discovered in a recent study. . . . → Read More: Algae Feed Proposed to Enrich Farm Salmon Fatty Acids Drug maker Novartis is acquiring Selexys Pharmaceuticals Corp., a developer of treatments for pain episodes associated with sickle cell disease, for $665 million. . . . → Read More: Novartis Acquires Sickle-Cell Drug Developer A synthetic porous material developed to deliver drugs to the skin was shown in lab tests to prevent the growth of bacteria on its surfaces. . . . → Read More: Nanotech Material Found Having Anti-Bacterial Properties Genomic analysis of tumors, a growing practice for diagnosing cancer in individuals, is shown to be feasible when conducted routinely throughout a cancer care center. . . . → Read More: Large-Scale Cancer Gene Profiling Seen as Feasible First results from a late-stage clinical trial shows a synthetic antibody reduces the number of days with migraines per month among people with episodic or infrequent migraines. . . . → Read More: Trial Shows Antibody Reduces Days with Migraines A new enterprise, spun-off from Harvard University stem cell labs, aims to make stem cell transplants from bone marrow safer and more reliable. . . . → Read More: Blood Stem Cell Start-Up Launches, Earns $48.5M Funding A company with a technology for converting drugs given by intravenous infusion into pills and capsules was acquired Grünenthal Group, a provider of pain medications. . . . → Read More: Infusion-to-Oral Drug Delivery Company Acquired A new type of cancer treatment that precisely attacks tumors with synthetic antibodies activated by laser beams is being tested in an early-stage clinical trial. . . . → Read More: Laser-Immunotherapy Now in Cancer Clinical Trial A two year-old medical device enterprise making a fertility tracker for women is raising $9.7 million in its first venture finance round. . . . → Read More: Fertility Device Company Gains $9.7M in Early Funds An experimental synthetic antibody was shown in a clinical trial to markedly reduce triglycerides and the types of cholesterol that contribute to heart disease. . . . → Read More: Antibody Leads to Sharp Triglyceride, Cholesterol Drop |
|||||
Copyright © 2024 Technology News and Literature - All Rights Reserved Powered by WordPress & Atahualpa |